Tikun Olam-Cannbit Pharmaceuticals Ltd

Informe acción TASE:TKUN

Capitalización de mercado: ₪30.6m

Tikun Olam-Cannbit Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Yifat Karib

Chief Executive Officer (CEO)

₪674.0k

Compensación total

Porcentaje del salario del CEO86.4%
Permanencia del CEO3.9yrs
Participación del CEOn/a
Permanencia media de la direcciónsin datos
Promedio de permanencia en la Junta Directiva4.6yrs

Actualizaciones recientes de la dirección

Recent updates

Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV:TKUN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Apr 28
Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV:TKUN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Risks To Shareholder Returns Are Elevated At These Prices For Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV:TKUN)

Jul 21
Risks To Shareholder Returns Are Elevated At These Prices For Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV:TKUN)

Would Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Be Better Off With Less Debt?

Oct 03
Would Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Be Better Off With Less Debt?

Is Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Weighed On By Its Debt Load?

Jun 03
Is Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Weighed On By Its Debt Load?

Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Is Carrying A Fair Bit Of Debt

Oct 17
Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Is Carrying A Fair Bit Of Debt

Is Tikun Olam - Cannbit Pharmaceuticals (TLV:TKUN) Using Debt Sensibly?

May 19
Is Tikun Olam - Cannbit Pharmaceuticals (TLV:TKUN) Using Debt Sensibly?

Shareholders Of Tikun Olam - Cannbit Pharmaceuticals (TLV:TKUN) Must Be Happy With Their 135% Total Return

Mar 19
Shareholders Of Tikun Olam - Cannbit Pharmaceuticals (TLV:TKUN) Must Be Happy With Their 135% Total Return

How Much Did Tikun Olam - Cannbit Pharmaceuticals'(TLV:TKUN) Shareholders Earn From Share Price Movements Over The Last Five Years?

Dec 02
How Much Did Tikun Olam - Cannbit Pharmaceuticals'(TLV:TKUN) Shareholders Earn From Share Price Movements Over The Last Five Years?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Yifat Karib en comparación con los beneficios de Tikun Olam-Cannbit Pharmaceuticals?
FechaCompensación totalSalarioIngresos de la empresa
Dec 31 2023n/an/a

-₪89m

Sep 30 2023n/an/a

-₪98m

Jun 30 2023n/an/a

-₪107m

Mar 31 2023n/an/a

-₪77m

Dec 31 2022₪674k₪582k

-₪48m

Sep 30 2022n/an/a

-₪38m

Jun 30 2022n/an/a

-₪27m

Mar 31 2022n/an/a

-₪30m

Dec 31 2021₪850k₪565k

-₪33m

Compensación vs. Mercado: La compensación total de Yifat($USD177.55K) está por debajo de la media de empresas de tamaño similar en el mercado IL ($USD431.63K).

Compensación vs. Ingresos: La compensación de Yifat ha sido consistente con los resultados de la empresa en el último año.


CEO

Yifat Karib (50 yo)

3.9yrs

Permanencia

₪674,000

Compensación

Ms. Yifat Karib is CEO from March 27, 2023, VP of Marketing & Government Relations from June 01, 2020 at Tikun Olam-Cannbit Pharmaceuticals Ltd respectively.


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Erez Navon
Director4.9yrssin datos2.7%
₪ 824.6k
Eitan Eliyahu
Chairman of the Board4.9yrs₪505.00ksin datos
Yaron Naor
Director4.9yrssin datos10.51%
₪ 3.2m
Yitzhak Ashkenazi
Independent Director4.6yrssin datos0.060%
₪ 18.4k
Orly Zilberman
Independent External Director3.2yrssin datossin datos
Ellit Mann Bitton
Independent External Director2.8yrssin datossin datos
Adi Zvulun
Director1.7yrssin datossin datos

4.6yrs

Permanencia media

53yo

Promedio de edad

Junta con experiencia: La junta directiva de TKUN se considera experimentada (4.7 años de antigüedad promedio).